Scarborough Advisors’s Ocular Therapeutix OCUL Stock Holding History

Scarborough Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.69K	Buy	+200	New	+$1.91K	﹤0.01%	609

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Scarborough Advisors's OCUL Position: Q1 2026 in Review

Scarborough Advisors opened a new position in Ocular Therapeutix (OCUL) in Q1 2026: 200 shares worth $1.69K. The stake represents ﹤0.01% of the portfolio and ranks #609 among its holdings.

269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Scarborough Advisors held 200 shares of Ocular Therapeutix worth $1.69K as of Q1 2026.
Ocular Therapeutix was a new Scarborough Advisors position in Q1 2026.
Ocular Therapeutix made up ﹤0.01% of Scarborough Advisors's portfolio in Q1 2026, its #609 holding.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Scarborough Advisors's 13F filing for Q1 2026, filed 7 May 2026.